Chronic Cough - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chronic Cough - Pipeline Review, H2 2016’, provides an overview of the Chronic Cough pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Cough, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Cough and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Cough

The report reviews pipeline therapeutics for Chronic Cough by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Cough therapeutics and enlists all their major and minor projects

The report assesses Chronic Cough therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Cough

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Cough

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Cough pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Afferent Pharmaceuticals, Inc.

AstraZeneca Plc

Conrig Pharma ApS

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

GW Pharmaceuticals Plc

NeRRe Therapeutics Ltd

Patara Pharma, Inc.

Pila Pharma AB

Afferent Pharmaceuticals, Inc.

AstraZeneca Plc

Conrig Pharma ApS

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd.

GW Pharmaceuticals Plc

NeRRe Therapeutics Ltd

Patara Pharma, Inc.

Pila Pharma AB

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chronic Cough ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chronic Cough Overview 7

Therapeutics Development 8

Pipeline Products for Chronic Cough - Overview 8

Pipeline Products for Chronic Cough - Comparative Analysis 9

Chronic Cough - Therapeutics under Development by Companies 10

Chronic Cough - Therapeutics under Investigation by Universities/Institutes 11

Chronic Cough - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Chronic Cough - Products under Development by Companies 14

Chronic Cough - Products under Investigation by Universities/Institutes 15

Chronic Cough - Companies Involved in Therapeutics Development 16

Afferent Pharmaceuticals, Inc. 16

AstraZeneca Plc 17

Conrig Pharma ApS 18

GlaxoSmithKline Plc 19

Glenmark Pharmaceuticals Ltd. 20

GW Pharmaceuticals Plc 21

NeRRe Therapeutics Ltd 22

Patara Pharma, Inc. 23

Pila Pharma AB 24

Chronic Cough - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 33

AF-219 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

cromolyn sodium - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

GRC-17536 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

GSK-2339345 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

lesogaberan - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

NEO-5937 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

orvepitant maleate - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

S-1226 - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules to Agonize CB1 and CB2 for Chronic Cough and Inflammatory Skin Diseases - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

ST-015 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

XEND-0501 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Chronic Cough - Dormant Projects 51

Chronic Cough - Discontinued Products 52

Chronic Cough - Product Development Milestones 53

Featured News & Press Releases 53

Sep 07, 2016: Patara Pharma Announces Positive Phase 2 Results for the Treatment of Refractory Chronic Cough in Patients with Idiopathic Pulmonary Fibrosis 53

May 16, 2016: Afferent Pharmaceuticals Presents Updated Positive Results with AF-219 from Phase 2B Chronic Cough Study at the 2016 American Thoracic Society International Conference 54

May 03, 2016: Patara Pharma Appoints Biotechnology Industry Leader John Schmid to Board of Directors 56

Sep 28, 2015: Afferent Pharmaceuticals Announces Positive Results in Phase 2b Chronic Cough Trial 56

Nov 25, 2014: Afferent Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency by 75% in Chronic Cough Is Published In The Lancet 57

Sep 09, 2013: Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 58

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Tables

List of Tables

Number of Products under Development for Chronic Cough, H2 2016 8

Number of Products under Development for Chronic Cough - Comparative Analysis, H2 ...

List of Tables

Number of Products under Development for Chronic Cough, H2 2016 8

Number of Products under Development for Chronic Cough - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Chronic Cough - Pipeline by Afferent Pharmaceuticals, Inc., H2 2016 16

Chronic Cough - Pipeline by AstraZeneca Plc, H2 2016 17

Chronic Cough - Pipeline by Conrig Pharma ApS, H2 2016 18

Chronic Cough - Pipeline by GlaxoSmithKline Plc, H2 2016 19

Chronic Cough - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 20

Chronic Cough - Pipeline by GW Pharmaceuticals Plc, H2 2016 21

Chronic Cough - Pipeline by NeRRe Therapeutics Ltd, H2 2016 22

Chronic Cough - Pipeline by Patara Pharma, Inc., H2 2016 23

Chronic Cough - Pipeline by Pila Pharma AB, H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 32

Chronic Cough - Dormant Projects, H2 2016 51

Chronic Cough - Discontinued Products, H2 2016 52

List of Figures

List of Figures

Number of Products under Development for Chronic Cough, H2 2016 8

Number of Products under Development for Chronic Cough - Comparative Analysis, H2 ...

List of Figures

Number of Products under Development for Chronic Cough, H2 2016 8

Number of Products under Development for Chronic Cough - Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports